Antitumor CAR T-cell Screening Platform: Many Are Called, but Few Are Chosen
- PMID: 35844172
- DOI: 10.1158/0008-5472.CAN-22-1739
Antitumor CAR T-cell Screening Platform: Many Are Called, but Few Are Chosen
Abstract
Treatment with T cells expressing chimeric antigen receptors (CAR) is a promising anticancer therapy. However, this approach has several limitations and has not yet been effectively applied to treat solid tumors. The study by Panowski and colleagues represents the first comparative analysis of multiple single chain fragment variable (scFv)-based anti-CD70 CAR T-cell clones for the development of a clinical product to treat renal cell carcinoma (RCC). Despite the risk of T-cell fratricide due to CD70 expression on T cells, CD70 CAR T cells were produced successfully thanks to the protective CD70 masking phenomenon. Two distinct classes of CAR T cells were identified with different memory phenotypes, activation statuses, and cytotoxic activity. CD70 CAR T cells presented high cytotoxic activity against RCC both in vitro in RCC cell lines and in vivo in patient-derived xenograft mouse models. The off-target effects expected on the lymphoid compartment were confirmed by tissue cross-reactivity staining and in a cynomolgus monkey preclinical model with CD3-CD70 bispecific antibody treatment. The efficacy and the toxicity profile of the lead CD70 CAR T-cell candidate instigated the researchers to proceed with upscaled clinical production. This article emphasizes the influence of the scFv of the CARs on their efficacy:toxicity balance. Ultimately, they successfully managed to develop a highly effective CAR T-cell candidate to treat a solid tumor by an allogeneic approach, thereby overcoming two major hurdles to broaden application of CAR T-cell therapy. See related article by Panowski et al., p. 2610.
©2022 American Association for Cancer Research.
Comment on
-
Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma.Cancer Res. 2022 Jul 18;82(14):2610-2624. doi: 10.1158/0008-5472.CAN-21-2931. Cancer Res. 2022. PMID: 35294525
Similar articles
-
Preclinical Development and Evaluation of Allogeneic CAR T Cells Targeting CD70 for the Treatment of Renal Cell Carcinoma.Cancer Res. 2022 Jul 18;82(14):2610-2624. doi: 10.1158/0008-5472.CAN-21-2931. Cancer Res. 2022. PMID: 35294525
-
The development of chimeric antigen receptor T-cells against CD70 for renal cell carcinoma treatment.J Transl Med. 2024 Apr 18;22(1):368. doi: 10.1186/s12967-024-05101-1. J Transl Med. 2024. PMID: 38637886 Free PMC article.
-
Tandem CAR-T cells targeting CD70 and B7-H3 exhibit potent preclinical activity against multiple solid tumors.Theranostics. 2020 Jun 18;10(17):7622-7634. doi: 10.7150/thno.43991. eCollection 2020. Theranostics. 2020. PMID: 32685008 Free PMC article.
-
Structure of and Signalling Through Chimeric Antigen Receptor.2022 Feb 7. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 1. 2022 Feb 7. In: Kröger N, Gribben J, Chabannon C, Yakoub-Agha I, Einsele H, editors. The EBMT/EHA CAR-T Cell Handbook [Internet]. Cham (CH): Springer; 2022. Chapter 1. PMID: 36122078 Free Books & Documents. Review.
-
Nanobody-based CAR-T cells for cancer immunotherapy.Biomark Res. 2022 Apr 25;10(1):24. doi: 10.1186/s40364-022-00371-7. Biomark Res. 2022. PMID: 35468841 Free PMC article. Review.
Cited by
-
Rationale for immune checkpoint inhibitors plus targeted therapy for advanced renal cell carcinoma.Heliyon. 2024 Apr 4;10(7):e29215. doi: 10.1016/j.heliyon.2024.e29215. eCollection 2024 Apr 15. Heliyon. 2024. PMID: 38623200 Free PMC article. Review.
-
Recent Advances in Single-Cell RNA-Sequencing of Primary and Metastatic Clear Cell Renal Cell Carcinoma.Cancers (Basel). 2023 Sep 26;15(19):4734. doi: 10.3390/cancers15194734. Cancers (Basel). 2023. PMID: 37835428 Free PMC article. Review.
Publication types
LinkOut - more resources
Full Text Sources
Research Materials